Extended anticoagulation after venous thromboembolism: should it be done? (2019)
- Authors:
- Autor USP: SOUZA, ROGÉRIO DE - FM
- Unidade: FM
- DOI: 10.1177/1753466619878556
- Subjects: TROMBOEMBOLISMO; ANTICOAGULANTES; RECIDIVA; HEMORRAGIA
- Language: Inglês
- Imprenta:
- Source:
- Título: Therapeutic advances in respiratory disease
- ISSN: 1753-4658
- Volume/Número/Paginação/Ano: v. 13, article ID 1753466619878550, 13p, 2019
- Este periódico é de acesso aberto
- Este artigo NÃO é de acesso aberto
-
ABNT
FERNANDES, Caio J et al. Extended anticoagulation after venous thromboembolism: should it be done?. Therapeutic advances in respiratory disease, v. 13, 2019Tradução . . Disponível em: https://doi.org/10.1177/1753466619878556. Acesso em: 28 fev. 2026. -
APA
Fernandes, C. J., Calderaro, D., Piloto, B., Hoette, S., Jardim, C. V. P., & Souza, R. de. (2019). Extended anticoagulation after venous thromboembolism: should it be done? Therapeutic advances in respiratory disease, 13. doi:10.1177/1753466619878556 -
NLM
Fernandes CJ, Calderaro D, Piloto B, Hoette S, Jardim CVP, Souza R de. Extended anticoagulation after venous thromboembolism: should it be done? [Internet]. Therapeutic advances in respiratory disease. 2019 ; 13[citado 2026 fev. 28 ] Available from: https://doi.org/10.1177/1753466619878556 -
Vancouver
Fernandes CJ, Calderaro D, Piloto B, Hoette S, Jardim CVP, Souza R de. Extended anticoagulation after venous thromboembolism: should it be done? [Internet]. Therapeutic advances in respiratory disease. 2019 ; 13[citado 2026 fev. 28 ] Available from: https://doi.org/10.1177/1753466619878556 - Incidência de hematomas subdurais espontâneos em casos de pacientes com hipertensão arterial pulmonar: Análise de um registro de cinco anos
- Elevated levels of inflammatory cytokines predict survival in idiopathic and familial pulmonary arterial hypertension. [Carta]
- Pulmonary hypertension in sickle cell disease
- Challenging the concept of adding more drugs in pulmonary arterial hypertension [Editorial]
- Pulmonary arterialhHypertension-related morbidity is prognostic for mortality
- Phase 3 Trial of Sotatercept for Treatment of Pulmonary Arterial Hypertension
- RV Fractional Area Change and TAPSE as Predictors of Severe Right Ventricular Dysfunction in Pulmonary Hypertension: A CMR Study
- 2016 – Um segundo passo [Editorial]
- Building the Future of Trial Design in PAH on Solid Ground
- Goal-oriented treatment of pulmonary arterial hypertension
Informações sobre o DOI: 10.1177/1753466619878556 (Fonte: oaDOI API)
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
